GHRS
GH Research PLC
NASDAQ: GHRS · HEALTHCARE · BIOTECHNOLOGY
$20.53
+7.15% today
Updated 2026-04-30
Market cap
$1.26B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.79
Dividend yield
—
52W range
$9 – $25
Volume
0.2M
GH Research PLC (GHRS) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-289000.00 | $-330000.00 | $-15.28M | $-26.20M | $-33.34M | $-42.28M | $-43.55M |
| Capital expenditures | $104000.00 | $21000.00 | $104000.00 | $67000.00 | $100000.00 | $49000.00 | $121000.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $0.00 | $0.00 | $366000.00 | $1.67M | $2.29M | $1.17M | $8.50M |
| Free cash flow | $-393000.00 | $-351000.00 | $-15.39M | $-26.27M | $-33.44M | $-42.33M | $-43.67M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — |